Mark Purcell
Stock Analyst at Morgan Stanley
(1.05)
# 3,593
Out of 4,873 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $118.00 | -3.39% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $47.80 | +15.06% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $38.28 | +14.94% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $69.68 | +21.99% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $67.35 | +78.17% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $118.00
Upside: -3.39%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $47.80
Upside: +15.06%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $38.28
Upside: +14.94%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $69.68
Upside: +21.99%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $67.35
Upside: +78.17%